Panic disorder anxiety, fear, panic
Conditions
Interventions
Administration of unapproved drug ([11C]K-2])
Sponsors
Asami Takeshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) A person whose age is 20 or above and under 60 at the time of obtaining consent 2) A person whose sufficient capacity to consent was confirmed by the MacArthur Competence Assessment Tool (MacCAT) and whose written consent was obtained 3) A person who meets the diagnostic criteria of panic disorder in DSM-5-TR
Exclusion criteria
Exclusion criteria: 1) Pregnant, may be pregnant, lactating, or wishing to become pregnant immediately (For premenopausal women, blood hCG will be tested before registration to confirm its level is below 6 mIU/ml. Contraception is requested for both men and women until one week after the PET scan) 2) Hypersensitive to alcohol 3) History or comorbidity of schizophrenia spectrum disorder, neurodevelopmental disorder group, anorexia nervosa (DSM-5-TR), or dependence syndrome (ICD-10). 4) Neurological disease (e.g., spinocerebellar degeneration, Parkinson's disease, or other neurodegenerative disease, nonminor cerebral hemorrhage or stroke) or history of head injury with loss of consciousness. 5) History of cerebral malignancy 6) History of epilepsy 7) Currently taking perampanel or topiramate 8) Unsuitable for 3 Tesla MRI imaging (metal implants in the body that are not compatible with 3 Tesla MRI, tattoos (including art makeup) larger than one point, severe claustrophobia, or body shape that is not compatible with the MRI scanner) 9) Significant deformity of brain structures (including congenital and traumatic) 10) Blood tests with either AST or ALT > 150 IU/L or serum Cr > 1.5 mg/dl 11) Previous [11C]K-2 PET scan in another clinical trial 12) Participated in an unapproved nuclear medicine testing trial or clinical trial within 6 months before enrollment 13) Participated in any other clinical trial or clinical study within 12 weeks before enrollment (limited to those with invasion or intervention) 14) Other subjects deemed inappropriate as research subjects by the principal investigator or co-investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference of AMPA receptor density in the brain between the panic disorder patients and healthy controls (obtained in other studies) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Correlation between AMPA receptor density in the brain and clinical measurements in patients with panic disorder. 2) Correlation between functional connectivity and AMPA receptor density in the brain regions composing the connections where connectivity differed from healthy controls; Association between fALFF values and AMPA receptor density in brain regions where fALFF values differed from healthy controls. | — |
Contacts
Public ContactTakeshi Asami
Yokohama City University Hospital
Outcome results
None listed